发明公开
- 专利标题： AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES
- 专利标题（中）： 抗原蛋白抗体FGFR2IIIB抗体
-
申请号： EP14752705.5申请日： 2014-07-31
-
公开(公告)号： EP3027651A1公开(公告)日： 2016-06-08
- 发明人: HARDING, Thomas , PIERCE, Kristen , PATIL, Namrata , BRENNAN, Thomas , HAMBLETON, Julie
- 申请人： Five Prime Therapeutics, Inc.
- 申请人地址： Two Corporate Drive South San Francisco, CA 94080 US
- 专利权人： Five Prime Therapeutics, Inc.
- 当前专利权人： Five Prime Therapeutics, Inc.
- 当前专利权人地址： Two Corporate Drive South San Francisco, CA 94080 US
- 代理机构： Brasnett, Adrian Hugh
- 优先权： US201361861198P 20130801; US201361901732P 20131108; US201461933632P 20140130
- 国际公布： WO2015017600 20150205
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K39/00 ; A61P35/00
摘要：
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
公开/授权文献
- EP3027651B1 AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES 公开/授权日：2019-02-27
信息查询
